KUALA LUMPUR, Feb 24 (Bernama) — Public-listed healthcare company, Malaysian Genomics Resource Centre Berhad (MGRC), and its subsidiary, pathology services company Clinipath (Malaysia) Sdn Bhd (Clinipath) today announced the availability of Dtect Prostate+, an affordable genetic screening test that examines key genes associated with prostate cancer.
Prostate cancer (PCa) is the most common cancer affecting adult men. Typical symptoms of PCa are burning or pain during urination, difficulty urinating or trouble starting and stopping while urinating, frequent urges to urinate at night, loss of bladder control, decreased flow or velocity of the urine stream, and blood in urine. Early stages of PCa are often not symptomatic which makes it a difficult disease to detect early.
